Enclomiphene 25mg
An oral non-steroidal SERM investigated for hypothalamic-pituitary-gonadal axis stimulation and endogenous testosterone production.
Mechanism
Acts as an antagonist at hypothalamic and pituitary estrogen receptors to block estradiol negative feedback, thereby stimulating GnRH, LH, and FSH secretion to promote endogenous testosterone synthesis.
Dosing
Evaluated in research protocols at oral baseline quantities of 12.5 mg administered once daily.
Reconstitution
Supplied as an oral compound in pre-measured capsules requiring no reconstitution with bacteriostatic water or liquid diluents.
Storage
Store sealed in original airtight packaging at controlled room temperature, protected against moisture, excessive heat, and direct light exposure.
Mix & measure Enclomiphene 25mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Enclomiphene 25mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: —
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Lower-Dose Reference | 12.5 mg once daily | Oral capsule (N/A) |
| Higher-Dose Reference | 25 mg once daily | Oral capsule (N/A) |
Reconstitution Steps
- 1
Confirm the capsule unit strength against target laboratory protocol requirements (no liquid diluent is required).
- 2
Inspect the packaging integrity to verify seals are undamaged and desiccants remain intact.
- 3
Administer the designated solid unit orally at a consistent time each 24-hour cycle.
- 4
Immediately reseal the container to protect remaining units from atmospheric humidity and ambient light.
Supplies Needed
Peptide Vial
Provides 25 mg of enclomiphene citrate research compound per pre-measured unit
Insulin Syringes (U-100)
Not required; compound is intended strictly for oral experimental protocols
Bacteriostatic Water
Not required; solid oral dose forms do not undergo liquid reconstitution
Alcohol Swabs
Used for standard laboratory benchtop and handling hygiene
Why researchers study it
Endogenous testosterone stimulation
Fertility preservation pathways
Secondary hypogonadism models
Isomer-specific SERM pharmacology
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Enclomiphene citrate represents the purified trans-isomer of clomiphene citrate, engineered to eliminate the persistent estrogenic properties associated with the cis-isomer zuclomiphene. In preclinical and clinical investigation, this selective estrogen receptor modulator targets central regulatory nodes to evaluate endocrine signaling in hypogonadal models without initiating exogenous steroid suppression. Because traditional androgen administration typically downregulates the hypothalamic-pituitary-testicular axis and suppresses spermatogenesis, research models explore enclomiphene specifically to examine how selective hypothalamic feedback disruption alters gonadotropin dynamics. Laboratory investigations assess its capacity to maintain normal testicular volume and spermatogenic signaling while simultaneously elevating circulating androgen markers. Formulated primarily as an oral solid dosage form, enclomiphene bypasses the lyophilization and reconstitution workflows common to research peptides. It remains an investigational chemical subject to rigorous analytical validation, with ongoing academic interest focusing on receptor selectivity, endocrine kinetics, and safety profiles relative to conventional mixed SERMs.
References
- 1.Wiehle RD, et al., BJU Int., 2013 — Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics
- 2.Wiehle RD, et al., Fertil Steril., 2014 — Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II trial vs topical testosterone
- 3.Kaminetsky J, et al., J Sex Med., 2013 — Oral enclomiphene citrate stimulates endogenous testosterone and sperm counts vs testosterone gel in men with low testosterone
- 4.Kim ED, McCullough A, Kaminetsky J., BJU Int., 2016 — Enclomiphene raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone
- 5.Earl JA, Kim ED., Expert Rev Endocrinol Metab., 2019 — Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism
- 6.Krzastek SC, et al., J Urol., 2019 — Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allPT-141 10mg
A synthetic melanocortin receptor agonist evaluated in clinical and laboratory models for centrally regulated libido and sexual response.
View ProtocolRetatrutide 30mg
Investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways to evaluate metabolic rate and body mass reduction.
View ProtocolTirzepatide 30mg
Dual GIP and GLP-1 receptor agonist studied for glycemic control, profound weight reduction, and metabolic health.
View Protocol